BETTER prevention and screening: Personalized clinical visits for adults

Not Applicable

Completed

• Conditions: Cancer and chronic disease; Cancer

• Registration Number: ISRCTN21333761
• Lead Sponsor: niversity of Alberta

Brief Summary

2018 Protocol article in https://bmccancer.biomedcentral.com/articles/10.1186/s12885-018-4839-y protocol (added 12/03/2021) 2023 Interim results article in https://pubmed.ncbi.nlm.nih.gov/36690937/ qualitative findings (added 24/01/2023) 2023 Results article in https://pubmed.ncbi.nlm.nih.gov/37389679/ results (added 03/07/2023) 2023 Results article in https://pubmed.ncbi.nlm.nih.gov/37770854/ (added 29/09/2023)

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2016-12-19
• Study Completion: 2022-07-28
• Last Update Posted: 9 October 2023

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 115

Inclusion Criteria

1. 40-65 years of age
2. Men and women
3. Able to give written informed consent
4. Cancer survivors who are low risk breast and/or colorectal and/or prostate cancer survivors
5. Patients without a personal history of breast, colorectal or prostate cancer
6. Patients on whom the researchers can obtain access to their medical records for the previous three years
7. Patients who are able to attend in-person preventions visits at their primary care site
8. Patients who are not receiving active treatment (i.e., systemic and/or radiation therapy) for cancer

Exclusion Criteria

1. Unable to give written informed consent for reasons of language, literacy, or competence
2. Unable to access their medical history for the previous three years
3. Receiving active treatment for cancer (i.e., systemic and/or radiation therapy)

*Prophylactic or hormone treatments (e.g., aromatase inhibitors) are not exclusion criteria. Physicians may request that a particular patient not be invited and the rationale for exclusion will be captured (e.g. patient too frail)

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Proportion of cancer and chronic disease prevention and screening (CCDPS) actions for which the patient was eligible at baseline that are met (according to pre-defined targets) at 12-month follow-up.

Secondary Outcome Measures

Name	Time	Method
<br> 1. Proportion of patients meeting the evidence-based targets will be measured by tracking specific cancer and chronic disease prevention and screening actions (e.g. mammograms completed, alcohol consumption reduced, screening for poverty) longitudinally at 6, 12, 18 and 24 months<br> 2. Number of targeted cancer and chronic disease prevention and screening actions that patients randomized to the intervention group were deemed eligible to improve at baseline that are met (according to pre-defined targets) at 24-month follow-up<br>